Complete Surgical Resection Improves Outcomes for Localized Primary Angiosarcoma of Bone
the Cancer Therapy Advisor take:
According to a new study published in the American Journal of Clinical Oncology, complete surgical resection of primary angiosarcoma of bone is associated with better outcomes.
For the retrospective study, researchers sought to analyze treatments with activity and survival of patients with primary angiosarcoma of bone. They identified 60 patients with a median age of 54 year who were treated between 1980 and 2009.
Lesions were commonly found in the femur and pelvis, and 40% of patients had metastatic disease at the time of diagnosis. Nearly 72% of patients underwent surgery and about 70% of those patients achieved surgical complete remission. About 28% of patients received radiotherapy, 13 of those with localized disease received chemotherapy, and 15 of those with metastatic disease received chemotherapy.
Results showed that the 5-year overall survival was 20%. Specifically, the 5-year overall survival was 33% for those with localized disease and 0% for those with metastatic disease. Patients without metastatic disease had improved overall after achieving surgical complete remission and adjuvant chemotherapy with cisplatin, doxorubicin, and ifosfamide.
Of the 15 patients who received chemotherapy for metastatic disease, two RECIST partial responses were observed out of 13 evaluable patients, 1 of whom received paclitaxel and the other who received doxorubicin. Two patients had stable disease.
Complete surgical resection of primary angiosarcoma of bone is associated with better outcomes.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Opinion: Understanding the FDA's Take on Cannabidiol
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer
- Opioid Use and Cancer
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk